Financials data is unavailable for this security.
View more
Year on year Golden Throat Holdings Group Co Ltd 's revenues fell -3.09% from 992.01m to 961.38m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 281.22m to 250.16m, a -11.04% decrease.
| Gross margin | 72.29% |
|---|---|
| Net profit margin | 26.06% |
| Operating margin | 38.37% |
| Return on assets | 13.01% |
|---|---|
| Return on equity | 19.34% |
| Return on investment | 19.26% |
More ▼
Cash flow in CNYView more
In 2023, Golden Throat Holdings Group Co Ltd increased its cash reserves by 11.40%, or 100.97m. The company earned 238.84m from its operations for a Cash Flow Margin of 24.84%. In addition the company used 59.67m on investing activities and also paid 79.38m in financing cash flows.
| Cash flow per share | 0.4483 |
|---|---|
| Price/Cash flow per share | 6.92 |
| Book value per share | 1.91 |
|---|---|
| Tangible book value per share | 1.91 |
More ▼
Balance sheet in CNYView more
| Current ratio | 2.04 |
|---|---|
| Quick ratio | 1.93 |
| Total debt/total equity | 0.3915 |
|---|---|
| Total debt/total capital | 0.2814 |
More ▼
Growth rates in CNY
Year on year, growth in dividends per share increased 71.53% while earnings per share excluding extraordinary items fell by -11.04%. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked above the industry average relative to its peers.
| Div yield(5 year avg) | 12.55% |
|---|---|
| Div growth rate (5 year) | 38.94% |
| Payout ratio (TTM) | 153.30% |
| EPS growth(5 years) | 19.61 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -24.35 |
More ▼
